Implications and outcomes of MRD‐negative multiple myeloma patients with immunofixation positivity

Assessment of disease activity and depth of response continues to be a moving target in multiple myeloma (MM). Where conventional complete response (CR) used to signify attainment of the deepest response to therapy, we now have tools including next generation sequencing (NGS) and multi-parametric flow cytometry (MFC) that have allowed for further disease stratification.1, 2 Assessment for minimal residual disease (MRD) has allowed for the...